NASDAQ:DARE

Daré Bioscience - DARE Stock Forecast, Price & News

$1.06

+0.02 (+1.44%)

(As of 10/4/2022 03:59 PM ET)

Add

Compare

Today's Range: $1.03
▼
$1.09
50-Day Range: $1.00
▼
$1.26
52-Week Range: $0.92
▼
$2.51

Volume: 4,908 shs
Average Volume: 282,274 shs
Market Capitalization: $89.49 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Daré Bioscience MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 741.1% Upside
$9.00 Price Target
Short Interest: Healthy
1.66% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.49
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.30) to ($0.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

877th out of 1,087 stocks

Pharmaceutical Preparations Industry

432nd out of 546 stocks

3.5

Analyst's Opinion

Consensus Rating
Daré Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.00, Daré Bioscience has a forecasted upside of 741.1% from its current price of $1.07.
Amount of Analyst Coverage
Daré Bioscience has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.66% of the outstanding shares of Daré Bioscience have been sold short.
Short Interest Ratio / Days to Cover
Daré Bioscience has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Daré Bioscience has recently decreased by 3.42%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Daré Bioscience does not currently pay a dividend.
Dividend Growth
Daré Bioscience does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DARE.

1.9

News and Social Media Coverage

News Sentiment
Daré Bioscience has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Daré Bioscience this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for DARE on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Daré Bioscience insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.00% of the stock of Daré Bioscience is held by insiders.
Percentage Held by Institutions
Only 8.74% of the stock of Daré Bioscience is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Daré Bioscience are expected to decrease in the coming year, from ($0.30) to ($0.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Daré Bioscience is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Daré Bioscience is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Daré Bioscience has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Daré Bioscience (NASDAQ:DARE) Stock

Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its products in advanced clinical development include Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company's Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar and vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan, as well as DARE-PTB1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ADARE-204 and ADARE-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company entered into license agreement with Organon & Co. and Organon International GmbH to commercialize XACIATO. Daré Bioscience, Inc. is headquartered in San Diego, California.

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Stock News Headlines

October 3, 2022 | nasdaq.com

Daré Bioscience (NASDAQ:DARE) investors are sitting on a loss of 69% if they invested five years ago

September 30, 2022 | msn.com

Dare County Schools goes virtual Friday because of Ian's possible impacts

September 17, 2022 | marketwatch.com

Dare Bioscience to Participate in Two Upcoming Conferences

September 17, 2022 | seekingalpha.com

DARE Daré Bioscience, Inc.

September 15, 2022 | finance.yahoo.com

Daré Bioscience to Participate in Two Upcoming Conferences

September 15, 2022 | msn.com

Dare to be different

September 12, 2022 | msn.com

Dare to be optimistic

September 6, 2022 | finance.yahoo.com

Daré Bioscience to Participate in H.C. Wainwright 24th Annual Global Investment Conference

August 30, 2022 | seekingalpha.com

Dare Bioscience reports positive progress for cream for female sexual arousal disorder

August 24, 2022 | finance.yahoo.com

Daré Bioscience, Inc. Announces Global Licensing Rights to the Novel Antimicrobial Glycerol Monolaurate for Vaginal Health

August 24, 2022 | msn.com

Dare to Care raising awareness for Hunger Action Month

August 12, 2022 | finance.yahoo.com

Daré Bioscience (NASDAQ:DARE) shareholders have endured a 58% loss from investing in the stock five years ago

August 11, 2022 | msn.com

The DARE Program Is Back in Some School Districts — Here’s What to Know

August 11, 2022 | seekingalpha.com

Dare Bioscience GAAP EPS of $0.00, revenue of $10M

August 9, 2022 | seekingalpha.com

Dare Bioscience, Inc. (DARE) CEO Sabrina Johnson on Q2 2022 Results - Earnings Call Transcript

August 9, 2022 | finance.yahoo.com

Daré Bioscience Reports Second Quarter 2022 Financial Results and Provides a Company Update

August 2, 2022 | finance.yahoo.com

Daré Bioscience to Host Second Quarter 2022 Financial Results and Company Update Conference Call and Webcast on August 9, 2022

July 7, 2022 | finance.yahoo.com

Daré Bioscience to Participate in Maxim Group Women’s Health Panel

June 30, 2022 | marketwatch.com

Dare Bioscience License Agreement With Organon Becomes Fully Effective

June 30, 2022 | seekingalpha.com

Daré Bioscience signs agreement with Organon for bacterial vaginosis therapy

June 24, 2022 | finance.yahoo.com

Daré Bioscience Announces Partial Adjournment of Annual Meeting of Stockholders to July 14, 2022

June 23, 2022 | msn.com

Where Does the Term ‘Double Dog Dare’ Come From?

June 6, 2022 | finance.yahoo.com

Daré Bioscience to Participate in the 2022 BIO International Convention

June 6, 2022 | msn.com

Minister Dare hands over basketball development to IMC

June 4, 2022 | msn.com

North Wales: Time to say no to DARE?

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive DARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daré Bioscience and its competitors with MarketBeat's FREE daily newsletter.

DARE Company Calendar

Last Earnings: 11/10/2021
Today: 10/04/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DARE
CUSIP: N/A
CIK: 1401914
Web: www.darebioscience.com
Phone: (858) 926-7655
Fax: 617-494-1544
Employees: 16
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.00
High Stock Price Forecast: $17.00
Low Stock Price Forecast: $4.00
Forecasted Upside/Downside: +373.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.46)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,700,000.00
Net Margins: N/A
Pretax Margin: -301.94%
Return on Equity: -89.76%
Return on Assets: -58.86%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.03
Quick Ratio: 3.03

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.51 per share
Price / Book: 2.07

Miscellaneous

Outstanding Shares: 84,820,000
Free Float: 81,428,000
Market Cap: $89.49 million
Optionable: Not Optionable
Beta: 1.24

Key Executives

Ms. Sabrina Martucci Johnson (Age 55)
Pres, CEO, Sec. & Director
Comp: $643.48k

Ms. Lisa Walters-Hoffert (Age 63)
Chief Financial Officer
Comp: $439.33k

Mr. John A. Fair (Age 50)
Chief Strategy Officer
Comp: $435.83k

Mr. Mark Walters (Age 67)
VP of Operations

Ms. MarDee J. Haring-Layton (Age 46)
VP of Accounting & Fin.

Dr. David Friend
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DARE Stock - Frequently Asked Questions

Should I buy or sell Daré Bioscience stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daré Bioscience in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DARE shares.
View DARE analyst ratings or view top-rated stocks.
What is Daré Bioscience's stock price forecast for 2022?: 3 equities research analysts have issued twelve-month price targets for Daré Bioscience's stock. Their DARE share price forecasts range from $4.00 to $17.00. On average, they predict the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 741.1% from the stock's current price.
View analysts price targets for DARE or view top-rated stocks among Wall Street analysts.
How have DARE shares performed in 2022?: Daré Bioscience's stock was trading at $2.00 at the beginning of the year. Since then, DARE stock has decreased by 46.5% and is now trading at $1.07.
View the best growth stocks for 2022 here.
When is Daré Bioscience's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our DARE earnings forecast.

How were Daré Bioscience's earnings last quarter?: Daré Bioscience, Inc. (NASDAQ:DARE) issued its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.05. During the same period in the previous year, the business posted ($0.24) EPS.
What other stocks do shareholders of Daré Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Daré Bioscience investors own include FuelCell Energy (FCEL), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), Matinas BioPharma (MTNB), Novavax (NVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX) and Sorrento Therapeutics (SRNE).
What is Daré Bioscience's stock symbol?: Daré Bioscience trades on the NASDAQ under the ticker symbol "DARE."
How do I buy shares of Daré Bioscience?: Shares of DARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Daré Bioscience's stock price today?: One share of DARE stock can currently be purchased for approximately $1.07.
How much money does Daré Bioscience make?: Daré Bioscience (NASDAQ:DARE) has a market capitalization of $90.76 million. The biotechnology company earns $-38,700,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.
How can I contact Daré Bioscience?: Daré Bioscience's mailing address is 3655 NOBEL DRIVE SUITE 260, SAN DIEGO CA, 92122. The official website for the company is www.darebioscience.com. The biotechnology company can be reached via phone at (858) 926-7655, via email at innovations@darebioscience.com, or via fax at 617-494-1544.

This page (NASDAQ:DARE) was last updated on 10/4/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Daré Bioscience - DARE Stock Forecast, Price & News

Daré Bioscience MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month